The future developments in digital genome market

Agilent Technologies Inc., GE Healthcare, Dickinson and Company, Becton, Pacific Bioscience, Illumina, GenMark Diagnostics, Inc., Genomic Health, Inc., NanoString Technologies, Inc., and Inscripta Inc., are some of the providers of digital genome solutions. In December 2019, Inscripta Inc., had raised $125m in a series D funding round to accelerate the development of applications and commercialisation of its Onyx Digital Genome Engineering platform.

One of the fastest emerging and most profitable verticals within the healthcare and medical devices domain, global digital genome market size is estimated to be worth over $50.4bn by 2025. Following are some of the most prominent trends propelling the technology adoption.

Proliferation of ChIP-sequencing in epigenetics

The implementation of ChIP-sequencing has gained momentum over the past few years due to rapid evolution in epigenetic studies. Sequencing chip is mainly used to study and understand how transcription factors and other chromatin related proteins influence phenotypic mechanisms.

The applications of ChIP-sequencing help better understand the events of gene regulation and its relationship with numerous metabolic and genetic disorders. Growing research in the field of epigenetics, a strong demand for DNA/RNA sequencing, and subsequent adoption of computer aided Insilco drug discovery (CADD) will positively influence digital genome market trends.

Growing utilisation in livestock and agriculture

Digital genetic testing technologies have gained wide acceptance across the agriculture and livestock industry. These technologies have also expanded the scope of genomic studies in the dairy industry. Bovine genetic test is generally performed on livestock animals such as beef, dairy cow, and cattle.

This helps livestock owners identify farming animas that display suitable traits, such as efficient nutrient utilisation, faster weight gain, high milk yield, tenderness of meat, and high disease resistance, making them economically useful for food production.

Advanced genome research in developed countries 

Many developed countries are implementing digital genome technologies in advanced healthcare projects. For instance, the Genome Russia project is likely to provide lucrative opportunities to regional digital genome companies.

In addition, numerous government organisations such as the European Commission, National Institute of Health, and Genome Canada are focusing on streamlining volunteering process in genomic research clinical trials necessary for advancement of new tests and treatment of chronic diseases. In emerging economics on the other hand, lack of expertise regarding digital genome technologies may limit overall industry growth.

Digital genomics is bound to transform the way infectious and rare diseases are identified, studied, and treated in the near future. The use of modern gene editing technologies such as next-generation sequencing, computer aided drug delivery, bio-python, will play a key role in tailoring precision medicines that require individual genetic variability.

Hospitals and medical research institutions are implementing next-generation DNA and RNA sequencing for testing organs for rejection before transplant. A positive application outlook of digital genomics in diagnosis, transplants, drug discovery and development, and preventing adverse drug reactions will bolster global digital genome industry outlook.

You can view the report here.